2006
DOI: 10.1161/01.atv.0000219672.68024.bc
|View full text |Cite
|
Sign up to set email alerts
|

COX-2 in Cardiovascular Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
30
0
2

Year Published

2008
2008
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(33 citation statements)
references
References 23 publications
1
30
0
2
Order By: Relevance
“…There is a body of evidence in favor of the latter (19) . However, recent evidence indicates that it may be a mixture of the two enzymes (26,27) , a fact that would be in agreement with the early observation that the concentration of 6-oxo PGF1α, the stable end product of the metabolism of prostacyclin, is elevated in patients with atherosclerosis (28) .…”
Section: The Vascular Endotheliumsupporting
confidence: 85%
“…There is a body of evidence in favor of the latter (19) . However, recent evidence indicates that it may be a mixture of the two enzymes (26,27) , a fact that would be in agreement with the early observation that the concentration of 6-oxo PGF1α, the stable end product of the metabolism of prostacyclin, is elevated in patients with atherosclerosis (28) .…”
Section: The Vascular Endotheliumsupporting
confidence: 85%
“…13 Endothelial COX-1 from normal vessels may be more readily inhibited by NSAIDs than platelet COX-1, preventing endothelial PGI 2 formation but not platelet-derived TxA 2 . 14 It may be that the apparent selectivity of a given COX inhibitor is determined by a target cell's peroxide content and arachidonate availability, rather than selectivity for a particular isoform.…”
Section: The Prostaglandin Biosynthesis Quandarymentioning
confidence: 99%
“…Two main factors may infl uence relative levels of a particular transcript in heterogeneous cell samples; one is an effective up-or downregulation of its expression in one or more cell types present in the sample, and the other is the alteration of the proportion of cell types expressing that transcript. It is well-known that COX-1 is ubiquitously expressed ( 6,7 ). Therefore, the increase of COX-1 in AAA was probably due to the enhanced proportion of cells with high MVECs were seeded onto Matrigel in 96-well plates and exposed to 10 nmol/l of PGE 2 or Cay10598 (an EP-4 agonist).…”
Section: Ep-4-activation-mediated In Vitro Angiogenesismentioning
confidence: 99%